Overview
Needham released April 2026 prescription trend data based on IQVIA tracking covering glaucoma and dry eye medications from Alcon (NYSE:ALC) and Bausch + Lomb (NYSE:BLCO).
Alcon prescription trends
Among Alcon products, Rocklatan prescriptions were down 4% year-over-year, an outcome described as an improvement from the prior month. Rhopressa prescriptions fell 9% year-over-year, while Simbrinza declined 5% year-over-year. Eysuvis prescriptions decreased 10% year-over-year. Tryptyr reported an 11% month-over-month increase in prescriptions, although Alcon has indicated IQVIA may be under-reporting Tryptyr scripts. Pataday prescriptions showed a 1% year-over-year rise.
Tryptyr’s market share stood at 2.0% at the end of April, unchanged from the prior month. Alcon’s overall dry eye prescription share remained at 3.0% at month-end.
Bausch + Lomb prescription trends
Bausch + Lomb’s April data showed Vyzulta prescriptions increased 5% year-over-year. Xiidra prescriptions fell 12% year-over-year, while Miebo prescriptions rose 31% year-over-year. The company’s total dry eye prescription share reached 49.5% at the end of April, up from 48.4% at the end of the previous month.
Context and implications
The figures provide a month-end snapshot of prescription movement across specific glaucoma and dry eye products tracked by IQVIA and compiled by Needham. For Alcon, multiple products experienced year-over-year declines, offset in part by a small gain for Pataday and a month-over-month rise in Tryptyr that Alcon cautioned may be under-reported in the IQVIA dataset. For Bausch + Lomb, growth in Vyzulta and Miebo contributed to an increase in the company’s dry eye prescription share to 49.5%.
Data limitations
The Tryptyr note from Alcon that IQVIA may under-report scripts highlights a data caveat within the tracked figures. Aside from that qualification, the summary presents the percentage changes and share levels as reported for April 2026.